查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1999204

人类药物敏感性检测市场：按产品类型、技术、检测类型、病原体、应用和最终用户划分－2026-2032年全球市场预测

Human Antimicrobial Susceptibility Testing Market by Product, Technology, Test Type, Pathogen, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，人类药物敏感性测试市场价值将达到 41.6 亿美元，到 2026 年将成长至 44.3 亿美元，到 2032 年将达到 65 亿美元，复合年增长率为 6.55%。

主要市场统计数据
基准年 2025 41.6亿美元
预计年份：2026年 44.3亿美元
预测年份 2032 65亿美元
复合年增长率 (%) 6.55%

一篇极具影响力的引言，概述了临床、操作和技术因素的融合，这些因素将重塑全球抗菌药物敏感性测试实践。

人类药物敏感性检测正处于转折点，其驱动力来自临床压力、检查室工作流程的演变以及技术的快速成熟。随着多重细菌感染疾病的复杂性日益增加、抗药性机制的不断涌现以及对快速、有效结果的需求不断增长，临床团队对药物敏感性检测结果的可靠性和速度都提出了更高的要求。同时，研究机构和製药合作伙伴也越来越需要标准化、可重复的检测平台，以便将其整合到药物研发流程和转化研究中。

定义变革性的技术和商业性变革，这些变革加速了整个药敏试验工作流程中的自动化、分子杂合反应和软体整合。

抗菌药物敏感性检测领域正经历一场变革，这场变革的驱动力来自自动化、分子技术的整合以及软体驱动的决策支援。自动化系统正逐步减少人工操作所需的时间和操作误差，使检查室能够在不相应增加人员配置的情况下扩大检测能力。软体平台进一步强化了这项变革，这些平台能够整合检测结果、进行趋势分析并提供以合理用药为重点的报告，从而使抗菌药物敏感性检测（AST）从一项独立的检查室操作转变为临床决策流程中不可或缺的一部分。

评估美国在 2025 年实施的关税变更对检验材料采购和实验室持续营运的累积影响和供应链影响。

2025年关税措施和贸易政策调整的实施，对与抗菌药物敏感性检测相关的检查室、製造商和分销网络产生了复杂的下游影响。关键进口设备、试剂和组件的进口前置作业时间增加以及监管摩擦延长了采购週期，迫使采购团队重新评估总到岸成本。因此，供应链规划正从週期性采购转向持续的风险规避和多源采购策略。

将产品、技术、测试类型、应用、最终用户和病原体维度与实际采购和验证要求连结起来的综合细分洞察。

一套精细的细分框架揭示了临床需求、技术能力和采购行为如何在产品、技术、检测类型、应用、最终用户和病原体等维度上相互交织。产品差异化涵盖仪器、试剂和耗材以及软体，其中仪器又细分为桌上型和无人值守式两种类型，试剂和耗材则包括试剂盒、试剂盘、培养基和试纸条。每个类别都为检查室带来了独特的验证、库存和成本的考量。这种细緻的产品级分析指南确定采购优先顺序。桌上型平台优先考虑空间节省和柔软性，而无人值守式系统则优先考虑处理能力和整合性。

关键区域洞察揭示了法律规范、基础设施投资和製造业趋势如何影响美洲、欧洲、中东和非洲以及亚太地区的采用。

区域趋势正在重塑美洲、欧洲、中东和非洲（EMEA）以及亚太地区的采购偏好、监管参与和创新应用。在美洲，对快速诊断和集中式检测网路整合的高度重视，推动了对高通量自动化平台和整合资讯学的需求，以支援倡议。该地区的检查室越来越注重快速交付检测结果和扩充性，以应对复杂的病例量，这影响了仪器和耗材的选择。

分析供应商的策略，优先考虑互通性、基于耗材的服务模式和监管合规性，以加强临床和商业性地位。

抗菌药物敏感性检测领域的主要企业正日益关注平台间的互通性、以耗材主导的服务模式以及支持临床决策和合理使用抗菌药物的数据分析。供应商正透过改进与实验室资讯系统的整合、提供自动化解读报告以及生命週期服务来提升提案价值，从而减轻最终用户的检验负担。这些策略倡议优先考虑与临床网络建立长期伙伴关係，而非一次性的仪器销售。

为供应商和检查室提供切实可行的策略建议，以增强整个药敏试验操作的韧性、互通性和临床影响。

产业领导者应采取平衡策略，在推进自动化和分子检测整合的同时，保持手动和分散式检测环境的柔软性。优先投资模组化和可互通平台，将使检查室能够在无需巨额资本投入的情况下扩展检测能力。同时，与本地试剂生产商和经销商建立牢固的伙伴关係，将增强供应韧性，并降低对单一供应商的依赖。

采用透明的混合方法研究途径，结合文献整合、与关键相关人员的访谈以及交叉检验资料的三角测量，以确保分析的严谨性。

本调查方法结合了系统性的第二手资料收集、有针对性的一手研究和严谨的资料三角验证，确保了研究结果的可靠性和可重复性。二手研究包括对同侪审查文献、监管指导文件、技术白皮书和公共采购政策的结构化审查，从而建立了技术能力、检验标准和监管预期方面的客观基准。这一基础层指南了一手研究的设计和分析假设的建构。

为了指导药敏试验的永续引入和临床整合，总结了技术、操作和监管要求。

总之，药物敏感性检测正从单纯的实验室工作发展成为一项综合性的临床工具，支持快速治疗决策、合理用药和转化研究。技术进步，特别是自动化、分子混合工作流程和软体驱动的报告功能，带来了新的效率和临床价值，但也增加了检验、采购和供应链管理的复杂性。相关人员必须仔细权衡这些利弊，同时兼顾速度、准确性和操作可行性。

最终，现实的实验、严格的检验以及与最终用户的持续合作对于易感性测试的创新至关重要，才能带来更好的患者治疗效果和加强公共卫生准备。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：人类药物敏感度检测市场：依产品划分

  • 装置
    • 桌面型
    • 走开
  • 试剂和耗材
    • 磁碟
    • 成套工具
    • 媒体
    • 条
  • 软体

第九章：人类药物敏感性检测市场：依技术划分

  • 自动化系统
    • 微型扫描系统
    • 凤凰系统
    • 维泰克系统
  • 纸锭扩散法
  • 渐变条
  • 微量稀释法
  • 分子方法

第十章：依检测方法分類的人体药物敏感性检测市场

  • 自动化测试
  • 手动测试
    • 琼脂稀释法
    • 肉汤微量稀释法
    • 纸锭扩散法
    • 渐变条

第十一章 人类药物敏感性检测市场（依病原体划分）

  • 真菌
  • 革兰氏阴性菌
    • 肠桿菌科
    • 非肠桿菌科
  • 革兰氏阳性菌
  • 分枝桿菌

第十二章：人类药物敏感性检测市场：依应用领域划分

  • 临床诊断
  • 製药
  • 研究

第十三章：人类药物敏感性检测市场：依最终用户划分

  • 诊所
  • 测试机构
  • 医院
  • 研究机构

第十四章：人类药物敏感性检测市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：人类药物敏感性检测市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：人类药物敏感性检测市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国人类药物敏感性测试市场

第十八章：中国人体药物敏感性检测市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Accelerate Diagnostics Inc.
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Bruker Corporation
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • HiMedia Laboratories Pvt. Ltd.
  • Liofilchem Srl
  • Luminex Corporation
  • QIAGEN NV
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-4E27A4DF1227

The Human Antimicrobial Susceptibility Testing Market was valued at USD 4.16 billion in 2025 and is projected to grow to USD 4.43 billion in 2026, with a CAGR of 6.55%, reaching USD 6.50 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.16 billion
Estimated Year [2026] USD 4.43 billion
Forecast Year [2032] USD 6.50 billion
CAGR (%) 6.55%

High-impact introduction outlining the converging clinical, operational, and technological forces reshaping antimicrobial susceptibility testing practices globally

The landscape of human antimicrobial susceptibility testing is at an inflection point driven by converging clinical pressures, evolving laboratory workflows, and accelerating technology maturation. Clinical teams confront increasing diagnostic complexity as polymicrobial infections, resistance mechanisms, and the need for rapid actionable results demand both robustness and speed in susceptibility outputs. At the same time, research and pharmaceutical partners are intensifying their demand for standardized, reproducible testing platforms that can integrate with drug development pipelines and translational studies.

Laboratories face competing priorities: maintaining regulatory compliance, reducing turnaround times, and optimizing reagent and instrument utilization while managing constrained budgets and skilled workforce shortages. These operational realities are reshaping procurement criteria, shifting the emphasis toward systems that deliver automation, connectivity, and validated performance across diverse specimen types. The introduction of advanced molecular and phenotypic hybrid workflows is redefining the role of AST as a bridge between identification and therapeutic stewardship.

Given these pressures, stakeholders must reconcile near-term clinical imperatives with long-term strategic investments. Cross-functional collaboration among clinicians, microbiologists, informaticians, and procurement teams is essential to translate diagnostic intelligence into improved patient outcomes. This introduction establishes the critical context and the main vectors of change that inform the deeper analysis in subsequent sections

Defining transformative technological and commercial shifts that are accelerating automation, molecular hybridization, and software integration across susceptibility testing workflows

The field of antimicrobial susceptibility testing is undergoing transformative shifts driven by automation, molecular integration, and software-enabled decision support. Automated systems are progressively reducing manual hands-on time and variability, enabling laboratories to scale capacity without proportionally expanding headcount. This transformation is reinforced by software platforms that consolidate results, enable trend analysis, and provide stewardship-focused reporting-shifting AST from a standalone laboratory procedure to an integral part of clinical decision pathways.

Parallel advances in molecular methods are enabling targeted detection of resistance determinants that complement phenotypic susceptibility outputs. Hybrid workflows that combine rapid molecular screening with confirmatory phenotypic testing are emerging as pragmatic solutions that balance speed and clinical relevance. Additionally, reagent and consumable innovations-such as pre-formulated media, stabilized strips, and kit-based reagents-are simplifying routine workflows and improving reproducibility across decentralized testing environments.

These shifts are also catalyzing changes in commercial strategy: vendors are prioritizing interoperable platforms, open data standards, and service models that extend beyond capital sales into consumable-based and data-driven revenue streams. As a result, clinical laboratories and research organizations must adapt procurement, validation, and IT integration approaches to fully realize the potential of these transformative technologies

Assessing the cumulative operational and supply chain consequences of United States tariff changes implemented in 2025 on testing procurement and laboratory continuity

The introduction of tariff measures and trade policy adjustments in 2025 has created complex downstream effects for laboratories, manufacturers, and distribution networks involved in antimicrobial susceptibility testing. Increased import duties and regulatory friction on key imported instruments, reagents, and components have amplified procurement lead times and prompted procurement teams to reassess total landed costs. As a consequence, supply chain planning has moved from periodic purchasing toward continuous risk mitigation and multi-sourcing strategies.

Manufacturers have responded by reassessing their global manufacturing footprints, increasing local production in tariff-affected jurisdictions, and reconfiguring supply networks to mitigate cost volatility. These shifts have altered decisions about inventory buffering, strategic stockpiling of critical consumables, and contractual terms with distributors. For laboratories, the practical implications include extended validation timelines for newly sourced products, potential substitutions that require cross-validation, and closer scrutiny of vendor service models to ensure continuity in testing capabilities during transition periods.

Looking ahead, sustained tariff-driven disruption can incentivize regional supply resilience and spur investments in domestic reagent and instrument production. At the same time, stakeholders must monitor regulatory harmonization efforts and trade negotiations that could ease friction. In this environment, flexible procurement strategies, enhanced supplier collaboration, and forward-looking validation protocols will be essential to preserve testing continuity and clinical reliability

Integrated segmentation insights linking product, technology, test type, application, end-user, and pathogen dimensions to practical procurement and validation imperatives

A nuanced segmentation framework reveals where clinical need, technological capability, and procurement behavior intersect across product, technology, test type, application, end user, and pathogen dimensions. Product differentiation encompasses instruments, reagents and consumables, and software, with instruments subdivided by bench top and walk-away modalities and reagents and consumables including discs, kits, media, and strips-each category driving distinct validation, inventory, and cost considerations for laboratories. This product-level granularity informs procurement priorities: bench top platforms often emphasize local footprint and flexibility, whereas walk-away systems prioritize throughput and integration.

Technology segmentation spans automated systems, disk diffusion, gradient strip, microdilution, and molecular methods; within automation, platform-level differentiation between MicroScan-style, Phoenix-style, and fully integrated Vitek-style systems determines interoperability and laboratory workflow redesign. Test type distinctions between automated testing and manual testing-where manual approaches include agar dilution, broth microdilution, disk diffusion, and gradient strip-highlight trade-offs between analytical precision and operational scalability. Applications range from clinical diagnostics to pharmaceutical development and research, with each use case imposing unique demands on validation rigor, traceability, and data integration.

End users such as clinics, diagnostic laboratories, hospitals, and research institutes each face different throughput profiles, capital constraints, and regulatory expectations, which influence adoption curves across the product and technology spectrum. Pathogen classification across fungi, gram negative bacteria, gram positive bacteria, and mycobacteria-along with finer distinctions such as Enterobacteriaceae versus non-Enterobacteriaceae within gram negatives-shapes reagent formulation needs, interpretive criteria, and susceptibility endpoint determination. Understanding these interdependent segmentation layers enables stakeholders to prioritize investments and tailor operational roadmaps

Critical regional insights revealing how regulatory frameworks, infrastructure investment, and manufacturing dynamics are shaping adoption across the Americas, EMEA, and Asia-Pacific

Regional dynamics are reshaping procurement preferences, regulatory interaction, and innovation diffusion across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. In the Americas, a strong emphasis on rapid diagnostics and consolidation of centralized testing networks is driving demand for high-throughput automated platforms and integrated informatics that support stewardship initiatives. Laboratories in this region are increasingly focused on rapid turnaround and scalability to manage complex caseloads, which influences choices in instruments and consumables.

Europe, Middle East & Africa present a heterogeneous landscape in which regulatory harmonization efforts, public health priorities, and fiscal constraints create diverse adoption patterns. In parts of this geography, stringent regulatory pathways and centralized procurement models favor validated, standardized solutions; in other areas, decentralized laboratories prioritize cost-effective manual methods and localized reagent solutions. Asia-Pacific demonstrates rapid adoption of automation and molecular hybrid approaches, supported by expanding domestic manufacturing capabilities and strong investment in laboratory infrastructure. This region's scale and manufacturing density also make it a focal point for supply chain reconfiguration and reagent localization efforts.

Across all regions, local regulatory frameworks, reimbursement models, and workforce availability will continue to moderate adoption rates and shape vendor strategies. A clear understanding of regional priorities is essential for tailoring market entry, service models, and distribution partnerships that align with local laboratory operations and clinical governance

Analyzing vendor strategies that prioritize interoperability, consumable-based service models, and regulatory compliance to strengthen clinical and commercial positioning

Leading companies in the antimicrobial susceptibility testing ecosystem are increasingly oriented toward platform interoperability, consumable-driven service models, and data analytics that support clinical decision-making and antimicrobial stewardship objectives. Vendors are enhancing their value propositions by integrating laboratory information systems connectivity, automating interpretive reporting, and offering lifecycle services that reduce the validation burden on end users. These strategic moves prioritize long-term partnerships with clinical networks over single-transaction equipment sales.

Competitive differentiation is also emerging through reagent innovation, such as stabilized kits and simplified media formulations that reduce variability and improve shelf stability across diverse laboratory environments. Manufacturers are investing in modular systems that enable incremental upgrades, protecting capital investments while offering pathways to higher throughput and expanded test menus. Strategic alliances between instrument providers and molecular assay developers are accelerating hybrid workflows that can quickly translate resistance determinant detection into actionable susceptibility guidance.

Finally, companies are intensifying focus on regulatory compliance and localized support, recognizing that rapid service response and robust post-market surveillance are critical for clinical trust. This combination of product innovation, service orientation, and regulatory rigor defines the competitive contours of the market and informs procurement and partnership choices by hospitals, reference laboratories, and research organizations

Actionable strategic recommendations for vendors and laboratories to enhance resilience, interoperability, and clinical impact across susceptibility testing operations

Industry leaders should pursue a balanced strategy that advances automation and molecular integration while preserving flexibility for manual and decentralized testing contexts. Prioritizing investments in modular, interoperable platforms will allow laboratories to scale capabilities without committing to prohibitive capital outlays. Concurrently, establishing robust partnerships with regional reagent manufacturers and distributors will enhance supply resilience and reduce dependency on single-source supply chains.

Operationally, embedding data analytics and stewardship-oriented reporting into platform design will increase clinical impact and support hospital governance objectives. Vendors and laboratories alike should collaborate to standardize data formats and adopt APIs that facilitate integration with electronic health records and infection control systems. From a regulatory and quality perspective, accelerating validation pipelines through pre-approved protocols and harmonized method comparison studies will reduce time to deployment and ensure consistent performance across diverse settings.

Finally, stakeholders should adopt dynamic procurement approaches that incorporate total cost of ownership, service responsiveness, and validation burden into purchasing decisions. By aligning commercial models with clinical workflows and long-term support commitments, industry leaders can unlock sustainable adoption and improved patient outcomes while mitigating operational and supply chain disruptions

Transparent mixed-methods research approach combining literature synthesis, primary stakeholder interviews, and cross-validated data triangulation to ensure analytical rigor

The research methodology combines systematic secondary evidence gathering, targeted primary engagement, and rigorous data triangulation to ensure robust and reproducible insights. Secondary work included a structured review of peer-reviewed literature, regulatory guidance documents, technical white papers, and public procurement policies to establish a factual baseline for technology capabilities, testing standards, and regulatory expectations. This foundational layer informed the design of primary interactions and the framing of analytical hypotheses.

Primary research incorporated structured interviews with laboratory directors, clinical microbiologists, procurement officers, and industry executives to capture operational realities, procurement drivers, and vendor performance perceptions. These engagements were designed to probe validation practices, reagent handling, workflow constraints, and post-market service expectations. Responses were coded and synthesized to identify recurring themes, regional differentiators, and operational pain points that inform practical recommendations.

Quantitative and qualitative inputs were triangulated through cross-validation across data sources, ensuring consistency and identifying outliers. Methodological quality controls included reproducibility checks, analyst peer review, and an audit trail documenting source provenance. This mixed-methods approach supports defensible conclusions and actionable guidance tailored to clinical, research, and commercial stakeholders

Concise conclusion synthesizing technological, operational, and regulatory imperatives to guide sustainable adoption and clinical integration of susceptibility testing

In conclusion, antimicrobial susceptibility testing is evolving from a discrete laboratory task into an integrated clinical asset that supports rapid therapeutic decision-making, stewardship initiatives, and translational research. Technological advances-particularly in automation, molecular hybrid workflows, and software-enabled reporting-are unlocking new efficiencies and clinical value, while also introducing complexity in validation, procurement, and supply chain management. Stakeholders must navigate these trade-offs deliberately, balancing speed, accuracy, and operational feasibility.

Regulatory dynamics, regional manufacturing trends, and trade policy shifts add layers of strategic consideration that influence procurement, service models, and vendor selection. Successful organizations will be those that invest in interoperable platforms, maintain diversified supply relationships, and embed data analytics into clinical workflows to demonstrate measurable impact. Collaboration across clinical, laboratory, and commercial functions will be essential to translate technological potential into reliable, everyday practice.

Ultimately, the path forward requires pragmatic experimentation, rigorous validation, and sustained engagement with end users to ensure that innovations in susceptibility testing deliver improved patient outcomes and enhanced public health preparedness

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Human Antimicrobial Susceptibility Testing Market, by Product

  • 8.1. Instruments
    • 8.1.1. Bench Top
    • 8.1.2. Walk Away
  • 8.2. Reagents Consumables
    • 8.2.1. Discs
    • 8.2.2. Kits
    • 8.2.3. Media
    • 8.2.4. Strips
  • 8.3. Software

9. Human Antimicrobial Susceptibility Testing Market, by Technology

  • 9.1. Automated Systems
    • 9.1.1. MicroScan Systems
    • 9.1.2. Phoenix Systems
    • 9.1.3. Vitek Systems
  • 9.2. Disk Diffusion
  • 9.3. Gradient Strip
  • 9.4. Microdilution
  • 9.5. Molecular Methods

10. Human Antimicrobial Susceptibility Testing Market, by Test Type

  • 10.1. Automated Testing
  • 10.2. Manual Testing
    • 10.2.1. Agar Dilution
    • 10.2.2. Broth Microdilution
    • 10.2.3. Disk Diffusion
    • 10.2.4. Gradient Strip

11. Human Antimicrobial Susceptibility Testing Market, by Pathogen

  • 11.1. Fungi
  • 11.2. Gram Negative Bacteria
    • 11.2.1. Enterobacteriaceae
    • 11.2.2. Non Enterobacteriaceae
  • 11.3. Gram Positive Bacteria
  • 11.4. Mycobacteria

12. Human Antimicrobial Susceptibility Testing Market, by Application

  • 12.1. Clinical Diagnostics
  • 12.2. Pharmaceutical
  • 12.3. Research

13. Human Antimicrobial Susceptibility Testing Market, by End User

  • 13.1. Clinics
  • 13.2. Diagnostic Laboratories
  • 13.3. Hospitals
  • 13.4. Research Institutes

14. Human Antimicrobial Susceptibility Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Human Antimicrobial Susceptibility Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Human Antimicrobial Susceptibility Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Human Antimicrobial Susceptibility Testing Market

18. China Human Antimicrobial Susceptibility Testing Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Accelerate Diagnostics Inc.
  • 19.6. Becton, Dickinson and Company
  • 19.7. bioMerieux SA
  • 19.8. Bruker Corporation
  • 19.9. Danaher Corporation
  • 19.10. F. Hoffmann-La Roche AG
  • 19.11. HiMedia Laboratories Pvt. Ltd.
  • 19.12. Liofilchem S.r.l.
  • 19.13. Luminex Corporation
  • 19.14. QIAGEN N.V.
  • 19.15. Siemens Healthineers AG
  • 19.16. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH TOP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH TOP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BENCH TOP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALK AWAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALK AWAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY WALK AWAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISCS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISCS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISCS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MEDIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MEDIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MEDIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STRIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STRIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STRIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROSCAN SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHOENIX SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY VITEK SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICRODILUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICRODILUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICRODILUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MOLECULAR METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MICRODILUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRADIENT STRIP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY FUNGI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ENTEROBACTERIACEAE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ENTEROBACTERIACEAE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ENTEROBACTERIACEAE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NON ENTEROBACTERIACEAE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NON ENTEROBACTERIACEAE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY NON ENTEROBACTERIACEAE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM POSITIVE BACTERIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM POSITIVE BACTERIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM POSITIVE BACTERIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MYCOBACTERIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 233. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 234. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 235. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 237. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 239. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 240. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 241. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. GCC HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GRAM NEGATIVE BACTERIA, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. G7 HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. G7 HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 269. G7 HUMAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)